-
Something wrong with this record ?
On the solubility and lipophilicity of metallacarborane pharmacophores
J. Rak, B. Dejlová, H. Lampová, R. Kaplánek, P. Matějíček, P. Cígler, V. Král,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23506420
DOI
10.1021/mp300565z
Knihovny.cz E-resources
- MeSH
- HIV Protease Inhibitors chemistry pharmacology MeSH
- Cobalt chemistry pharmacology MeSH
- Humans MeSH
- Ligands MeSH
- Lipids chemistry MeSH
- Molecular Structure MeSH
- Drug Discovery MeSH
- Organometallic Compounds chemistry pharmacology MeSH
- Solubility MeSH
- Serum Albumin chemistry MeSH
- Boron Compounds chemistry pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Metallacarborane moieties have been identified as promising pharmacophores. The pharmaceutical use of such compounds is, however, complicated by their low solubility and tendency to self-assemble in aqueous solution. In this work, we estimated the solubilities of a vast series of metallacarboranes [cobalt bis(dicarbollide) derivatives] in pure water, saline, and saline with human serum albumin as a model of blood plasma. In addition, we determined the octanol-water partition coefficients (Pow) as a lipophilicity descriptor. Pow weakly correlates with the water solubility of metallacarboranes, whereas the ability of HSA to increase the solubility of metallacarboranes correlates well with their Pow values. Because metallacarboranes are known inhibitors of HIV protease, the possible correlation between Pow and the ability to inhibit HIV protease was investigated. Results from this study indicate that interaction of metallacarborane inhibitors with HIV protease is driven by specific binding rather than by promiscuous lipophilic interactions. The most promising candidates for further drug development were identified by ligand lipophilicity efficiency analysis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040871
- 003
- CZ-PrNML
- 005
- 20140114102326.0
- 007
- ta
- 008
- 140107s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/mp300565z $2 doi
- 035 __
- $a (PubMed)23506420
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rak, Jakub
- 245 10
- $a On the solubility and lipophilicity of metallacarborane pharmacophores / $c J. Rak, B. Dejlová, H. Lampová, R. Kaplánek, P. Matějíček, P. Cígler, V. Král,
- 520 9_
- $a Metallacarborane moieties have been identified as promising pharmacophores. The pharmaceutical use of such compounds is, however, complicated by their low solubility and tendency to self-assemble in aqueous solution. In this work, we estimated the solubilities of a vast series of metallacarboranes [cobalt bis(dicarbollide) derivatives] in pure water, saline, and saline with human serum albumin as a model of blood plasma. In addition, we determined the octanol-water partition coefficients (Pow) as a lipophilicity descriptor. Pow weakly correlates with the water solubility of metallacarboranes, whereas the ability of HSA to increase the solubility of metallacarboranes correlates well with their Pow values. Because metallacarboranes are known inhibitors of HIV protease, the possible correlation between Pow and the ability to inhibit HIV protease was investigated. Results from this study indicate that interaction of metallacarborane inhibitors with HIV protease is driven by specific binding rather than by promiscuous lipophilic interactions. The most promising candidates for further drug development were identified by ligand lipophilicity efficiency analysis.
- 650 _2
- $a sloučeniny boru $x chemie $x farmakologie $7 D001896
- 650 _2
- $a kobalt $x chemie $x farmakologie $7 D003035
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a inhibitory HIV-proteasy $x chemie $x farmakologie $7 D017320
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a lipidy $x chemie $7 D008055
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a organokovové sloučeniny $x chemie $x farmakologie $7 D009942
- 650 _2
- $a sérový albumin $x chemie $7 D012709
- 650 _2
- $a rozpustnost $7 D012995
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dejlová, Barbora $u -
- 700 1_
- $a Lampová, Hana $u -
- 700 1_
- $a Kaplánek, Robert $u -
- 700 1_
- $a Matějíček, Pavel $u -
- 700 1_
- $a Cígler, Petr $u -
- 700 1_
- $a Král, Vladimír $u -
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 10, č. 5 (2013), s. 1751-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23506420 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140114103030 $b ABA008
- 999 __
- $a ok $b bmc $g 1005267 $s 839383
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 10 $c 5 $d 1751-9 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20140107